botulinum toxin A longer acting (IPN10200) / Ipsen - LARVOL DELTA

LAURITE 3: A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=160 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=670 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Migraine

LAURITE 1: A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=309 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed

LAURITE 3: A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=160 | Not yet recruiting | Sponsor: Ipsen

New P3 trial

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=641 | Recruiting | Sponsor: Ipsen | Trial primary completion date: Jan 2027 ➔ Oct 2027

Trial primary completion date • CNS Disorders • Migraine

CLIN-10200-458: A study to assess the effectiveness and safety of IPN10200 over time in adults with moderate to severe wrinkle-like lines between the eyebrows (LAURITE 2) (clinicaltrialsregister.eu) - P2/3 | N=40 | Not yet recruiting | Sponsor: Ipsen Innovation

New P2/3 trial

LANTIMA: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Ipsen | Trial completion date: Oct 2027 ➔ Mar 2029 | Trial primary completion date: Oct 2027 ➔ Mar 2029

Trial completion date • Trial primary completion date • Movement Disorders

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=641 | Recruiting | Sponsor: Ipsen | Trial completion date: Jun 2027 ➔ Oct 2027 | Trial primary completion date: May 2027 ➔ Jan 2027

Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Pain

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=727 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2027 ➔ Aug 2027

Enrollment closed • First-in-human • Trial completion date

CATALPA: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Ipsen | N=94 ➔ 132

Enrollment change • CNS Disorders • Dystonia • Movement Disorders

LAURITE 2: A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=1300 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open

LAURITE 1: A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open

LAURITE 2: A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=1300 | Not yet recruiting | Sponsor: Ipsen

New P3 trial

CLIN-10200-454: A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults (clinicaltrialsregister.eu) - P1/2 | N=311 | Recruiting | Sponsor: Ipsen Innovation | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

LAURITE 1: A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Ipsen

New P3 trial

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma (Yahoo Finance) - "The ICC Tribunal’s decision confirms Ipsen’s full rights to its clinical stage toxin programs in the aesthetic field....'We continue to assess all options to maximize the value of IPN10200.'"

Commercial • Musculoskeletal Diseases

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=727 | Recruiting | Sponsor: Ipsen | Trial primary completion date: Mar 2026 ➔ Aug 2026

Trial primary completion date

Ipsen…announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. (The Manila Times) - "Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs placebo (primary endpoint). A longer duration of effect was also observed with a substantial majority of patients experiencing a clinically significant response at Week 24 compared with placebo and Dysport, defined as a score of "none” or "mild”. IPN10200 continued to show a greater response in line severity vs Dysport at Week 36. In this trial Dysport was shown to perform consistently with its profile."

P2 data • Dermatology

CATALPA: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Ipsen | Trial primary completion date: Feb 2026 ➔ Mar 2027

Trial primary completion date • CNS Disorders • Dystonia • Movement Disorders

LANTIMA: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Ipsen | Active, not recruiting ➔ Recruiting

Enrollment open • Movement Disorders

CATALPA: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Dystonia • Movement Disorders

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance (GlobeNewswire) - "H1 total sales growth of 11.4% at CER, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology; H1 core operating income of €656m, growing by 21.9% as reported, with a core operating margin of 36.0% of total sales, increasing by 3.6 points; Upgraded FY 2025 financial guidance: total-sales growth greater than 7.0% at CER (prior guidance: greater than 5.0% at CER); core operating margin greater than 32.0% of total sales (prior guidance: greater than 30%)"

Commercial • Dystonia • Neuroendocrine Tumor • Primary Biliary Cholangitis • Renal Cell Carcinoma

CATALPA: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Ipsen

New P2 trial • CNS Disorders • Dystonia • Movement Disorders

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=641 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=641 | Not yet recruiting | Sponsor: Ipsen

New P2 trial • CNS Disorders • Migraine • Pain